Agritech Business Centre
Conference Centre


Femtogenix was founded in 2015 to produce next generation payload molecules for use in antibody-drug conjugates for the treatment of cancer. Our drug discovery platform allows us to design molecules capable of binding to DNA, in a sequence-interactive manner, leading to potent cytotoxicity toward tumour cells. When attached to antibodies or other targeting moieties, these potent cytototoxic agents can be delivered directly to tumours with minimal general toxicities for patients. Our management and scientific teams consist of highly experienced scientists with the expertise and drive to translate our novel platform into tangible results for cancer patients.